$36.11
al cierre: Nov 11 EDT
$36.49
0.381.05%
Pre-comercialización: 5:21 PM EDT
Comments
Loading...
Travere Therapeutics Actividad de operaciones con información privilegiada
TVTXNASDAQ
Actividad de operaciones de insiders
Sigue la actividad de operaciones con información privilegiada más reciente de Travere Therapeutics. Mantente informado sobre las compras, ventas e impacto en el mercado recientes de las acciones de Travere Therapeutics.
¿Qué es la actividad interna?
La actividad de uso de información privilegiada involucra a personas con información privilegiada de la empresa, como ejecutivos, directores y empleados, que participan en transacciones con acciones de su propia empresa. Las transacciones de compra y venta de los iniciados proporcionan información valiosa sobre su confianza en el desempeño futuro de la empresa.
¿Qué están haciendo Travere Therapeutics Inc los iniciados?
En Travere Therapeutics Inc, la reciente actividad interna ha llamado la atención. Durante los últimos 30 días, los insiders han informado que han vendido un total de 15.20K acciones por valor de $1.22M, mientras tanto, los insiders han no reportar compras en los últimos 30 días.
Compras y ventas recientes notables de información privilegiada
- El agosto 28, 2025, Christopher Cline, la empresa CHIEF FINANCIAL OFFICER sold 470 acciones por $17.31 cada una.
- El septiembre 5, 2025, Christopher Cline, la empresa CHIEF FINANCIAL OFFICER sold 573 acciones por $18.51 cada una.
- El octubre 30, 2025, Peter Heerma, la empresa CHIEF COMMERCIAL OFFICER sold 2.66K acciones por $30 cada una.
Estadísticas de propiedad de Travere Therapeutics Inc
Acciones en circulación
89.472M
Acciones en manos de personas con información privilegiada
4.165M
Porcentaje de acciones en manos de personas con información privilegiada
4.65%
Acciones en manos de instituciones
49.633M
Porcentaje de acciones en manos de instituciones
55.5%
Nov 06, 2025 | SVP, CHIEF ACCOUNTING OFFICER | -5.87K | $30.01 | -$944.93K | SELL | -10.78% | 48.55K | Nov 04 | ||
Nov 04, 2025 | — | 0.00 | $25.99 | -$325.56K | SELL-OPTIONS | 0.00% | 55.50K | Oct 31 | ||
Nov 04, 2025 | CHIEF COMMERCIAL OFFICER | -6.67K | $35.00 | -$195.69K | SELL | -5.35% | 117.99K | Oct 31 - Nov 03 | ||
Oct 30, 2025 | CHIEF EXECUTIVE OFFICER | 0.00 | $22.89 | -$1.78M | SELL-OPTIONS | 0.00% | 419.17K | Oct 28 - Oct 29 | ||
Oct 30, 2025 | CHIEF COMMERCIAL OFFICER | -2.66K | $30.00 | -$79.86K | SELL | -2.09% | 124.66K | Oct 28 | ||
Sep 24, 2025 | CHIEF LEGAL OFFICER AND GC | 0.00 | $22.04 | -$59.20K | SELL-OPTIONS | 0.00% | 89.88K | Sep 22 | ||
Sep 05, 2025 | CHIEF FINANCIAL OFFICER | -573.00 | $18.51 | -$10.61K | SELL | -0.62% | 92.08K | Sep 03 - Sep 04 | ||
Aug 28, 2025 | CHIEF FINANCIAL OFFICER | -470.00 | $17.31 | -$8.14K | SELL | -0.50% | 92.66K | Aug 27 | ||
Jul 02, 2025 | CHIEF MEDICAL OFFICER | -815.00 | $14.65 | -$11.94K | SELL | -0.91% | 88.79K | Jul 01 | ||
May 05, 2025 | CHIEF FINANCIAL OFFICER | 3.14K | $21.05 | -$37.55K | SELL-OPTIONS | 3.48% | 93.13K | May 02 - May 05 | ||
May 05, 2025 | CHIEF EXECUTIVE OFFICER | 0.00 | $21.05 | -$398.35K | SELL-OPTIONS | 0.00% | 419.17K | May 02 - May 05 | ||
May 05, 2025 | CHIEF COMMERCIAL OFFICER | 3.15K | $21.05 | -$37.28K | SELL-OPTIONS | 2.52% | 128.22K | May 02 - May 05 | ||
May 05, 2025 | CHIEF RESEARCH OFFICER | 1.72K | $21.05 | -$67.32K | SELL-OPTIONS | 1.75% | 100.24K | May 02 - May 05 | ||
May 05, 2025 | CHIEF LEGAL OFFICER AND GC | 0.00 | $21.05 | -$103.57K | SELL-OPTIONS | 0.00% | 89.48K | May 02 - May 05 | ||
Apr 14, 2025 | CHIEF FINANCIAL OFFICER | -48.00 | $13.14 | -$630.94 | SELL | -0.05% | 89.99K | Apr 11 | ||
Feb 12, 2025 | SENIOR VICE PRESIDENT, R&D | 2.80K | $23.53 | -$122.36K | SELL-OPTIONS | 2.93% | 98.52K | Feb 10 - Feb 12 | ||
Feb 12, 2025 | SVP, GC & CORPORATE SECRETARY | 0.00 | $23.53 | -$188.24K | SELL-OPTIONS | 0.00% | 89.48K | Feb 10 - Feb 12 | ||
Feb 12, 2025 | SVP, CHIEF ACCOUNTING OFFICER | -9.24K | $20.81 | -$607.90K | SELL | -14.52% | 54.41K | Feb 11 | ||
Feb 12, 2025 | CHIEF COMMERCIAL OFFICER | 2.36K | $24.33 | -$137.28K | SELL-OPTIONS | 1.92% | 125.07K | Feb 10 - Feb 12 | ||
Feb 12, 2025 | CHIEF EXECUTIVE OFFICER | -11.38K | $24.04 | -$273.45K | SELL | -2.64% | 419.17K | Feb 11 | ||
Feb 12, 2025 | CHIEF MEDICAL OFFICER | 5.43K | $23.53 | -$60.43K | SELL-OPTIONS | 6.45% | 89.60K | Feb 10 - Feb 12 | ||
Feb 10, 2025 | — | 0.00 | $19.72 | -$45.60K | SELL-OPTIONS | 0.00% | 31.00K | Feb 06 | ||
Feb 04, 2025 | SENIOR VICE PRESIDENT, R&D | 12.55K | $19.78 | -$177.05K | GRANT | 15.09% | 95.72K | Jan 31 - Feb 03 | ||
Feb 04, 2025 | SVP, GC & CORPORATE SECRETARY | 12.55K | $19.78 | -$177.05K | GRANT | 16.31% | 89.48K | Jan 31 - Feb 03 | ||
Feb 04, 2025 | CHIEF EXECUTIVE OFFICER | 79.31K | $20.21 | -$1.02M | GRANT | 22.58% | 430.55K | Jan 31 - Feb 03 | ||
Feb 04, 2025 | CHIEF MEDICAL OFFICER | 24.73K | $20.12 | -$106.08K | GRANT | 41.60% | 84.17K | Jan 31 - Feb 04 | ||
Feb 04, 2025 | CHIEF COMMERCIAL OFFICER | 16.33K | $20.12 | -$103.94K | GRANT | 15.36% | 122.71K | Jan 31 - Feb 03 | ||
Feb 04, 2025 | CHIEF FINANCIAL OFFICER | 16.31K | $20.12 | -$104.46K | GRANT | 22.12% | 90.04K | Jan 31 - Feb 03 | ||
Feb 04, 2025 | SVP, CHIEF ACCOUNTING OFFICER | 9.65K | $20.12 | -$67.36K | GRANT | 17.87% | 63.65K | Jan 31 - Feb 03 | ||
Jan 23, 2025 | SENIOR VICE PRESIDENT, R&D | -2.44K | $19.46 | -$47.42K | SELL | -2.85% | 83.17K | Jan 22 | ||
Jan 23, 2025 | CHIEF EXECUTIVE OFFICER | -10.74K | $19.46 | -$208.92K | SELL | -2.97% | 351.24K | Jan 22 | ||
Jan 23, 2025 | SVP, GC & CORPORATE SECRETARY | -2.44K | $19.46 | -$47.42K | SELL | -3.07% | 76.93K | Jan 22 | ||
Jan 23, 2025 | — | 0.00 | $18.75 | -$40.00K | SELL-OPTIONS | 0.00% | 31.00K | Jan 23 | ||
Jan 23, 2025 | CHIEF COMMERCIAL OFFICER | -1.58K | $18.94 | -$30.00K | SELL | -1.47% | 106.37K | Jan 22 | ||
Jan 23, 2025 | CHIEF FINANCIAL OFFICER | -865.00 | $18.94 | -$16.38K | SELL | -1.16% | 73.73K | Jan 22 | ||
Jan 23, 2025 | SVP, CHIEF ACCOUNTING OFFICER | -925.00 | $18.94 | -$17.52K | SELL | -1.68% | 54.00K | Jan 22 | ||
Jan 06, 2025 | CHIEF MEDICAL OFFICER | -2.51K | $19.04 | -$47.72K | SELL | -4.05% | 59.44K | Jan 03 - Jan 06 | ||
Dec 27, 2024 | SVP, CHIEF ACCOUNTING OFFICER | 0.00 | $14.94 | -$68.23K | SELL-OPTIONS | 0.00% | 54.93K | Dec 26 | ||
Nov 25, 2024 | SVP, CHIEF ACCOUNTING OFFICER | 2.91K | $15.49 | -$31.21K | SELL-OPTIONS | 5.59% | 54.93K | Nov 25 | ||
Oct 04, 2024 | — | 0.00 | $12.60 | -$169.90K | SELL-OPTIONS | 0.00% | 51.00K | Oct 04 | ||
Sep 30, 2024 | — | 0.00 | $12.27 | -$143.12K | SELL-OPTIONS | 0.00% | 81.00K | Sep 30 | ||
Sep 10, 2024 | CHIEF MEDICAL OFFICER | -684.00 | $12.98 | -$8.88K | SELL | -1.09% | 61.95K | Sep 10 | ||
Sep 09, 2024 | SENIOR VICE PRESIDENT, R&D | 2.36K | $11.52 | -$50.54K | GRANT | 2.88% | 84.45K | Sep 05 - Sep 09 | ||
Sep 09, 2024 | SVP, GC & CORPORATE SECRETARY | 2.36K | $11.52 | -$50.54K | GRANT | 3.10% | 78.63K | Sep 05 - Sep 09 | ||
Sep 09, 2024 | CHIEF EXECUTIVE OFFICER | 11.38K | $11.52 | -$243.36K | GRANT | 3.24% | 361.98K | Sep 05 - Sep 09 | ||
Sep 09, 2024 | CHIEF MEDICAL OFFICER | 4.56K | $11.52 | -$25.24K | GRANT | 7.85% | 62.63K | Sep 05 - Sep 09 | ||
Sep 09, 2024 | CHIEF COMMERCIAL OFFICER | 4.56K | $11.52 | -$25.24K | GRANT | 4.41% | 107.96K | Sep 05 - Sep 09 | ||
Sep 09, 2024 | CHIEF FINANCIAL OFFICER | 4.26K | $11.52 | -$28.68K | GRANT | 6.06% | 74.59K | Sep 05 - Sep 09 | ||
Sep 05, 2024 | CHIEF FINANCIAL OFFICER | -514.00 | $9.51 | -$4.89K | SELL | -0.73% | 70.33K | Sep 04 | ||
Apr 12, 2024 | CHIEF FINANCIAL OFFICER | -54.00 | $6.74 | -$363.96 | SELL | -0.08% | 70.85K | Apr 11 | ||
Feb 02, 2024 | CHIEF EXECUTIVE OFFICER | 115.88K | $8.70 | -$166.44K | GRANT | 49.37% | 350.60K | Jan 31 - Feb 01 | ||
Feb 02, 2024 | SENIOR VICE PRESIDENT, R&D | 20.24K | $8.71 | -$41.50K | GRANT | 33.46% | 80.72K | Jan 31 - Feb 01 | ||
Feb 02, 2024 | SVP, CHIEF ACCOUNTING OFFICER | 10.68K | $8.53 | -$24.06K | GRANT | 25.84% | 52.02K | Jan 31 - Feb 01 | ||
Feb 02, 2024 | SVP, GC & CORPORATE SECRETARY | 20.24K | $8.71 | -$41.50K | GRANT | 36.11% | 76.27K | Jan 31 - Feb 01 | ||
Feb 02, 2024 | CHIEF COMMERCIAL OFFICER | 20.80K | $8.53 | -$35.79K | GRANT | 26.44% | 99.50K | Jan 31 - Feb 01 | ||
Feb 02, 2024 | CHIEF MEDICAL OFFICER | 22.83K | $8.53 | -$18.55K | GRANT | 64.76% | 58.07K | Jan 31 - Feb 01 | ||
Feb 02, 2024 | CHIEF FINANCIAL OFFICER | 21.18K | $8.53 | -$32.57K | GRANT | 42.60% | 70.90K | Jan 31 - Feb 01 | ||
Jan 25, 2024 | SVP, GC & CORPORATE SECRETARY | -2.06K | $8.96 | -$18.48K | SELL | -3.55% | 56.03K | Jan 23 | ||
Jan 25, 2024 | CHIEF EXECUTIVE OFFICER | -7.87K | $8.96 | -$70.54K | SELL | -3.25% | 234.72K | Jan 23 | ||
Jan 25, 2024 | CHIEF FINANCIAL OFFICER | -853.00 | $9.07 | -$7.74K | SELL | -1.69% | 49.72K | Jan 23 | ||
Jan 25, 2024 | SENIOR VICE PRESIDENT, R&D | -2.06K | $8.96 | -$18.48K | SELL | -3.30% | 60.48K | Jan 23 | ||
Jan 25, 2024 | SVP, CHIEF ACCOUNTING OFFICER | -910.00 | $9.07 | -$8.25K | SELL | -2.15% | 41.34K | Jan 23 | ||
Jan 25, 2024 | CHIEF COMMERCIAL OFFICER | -1.56K | $9.07 | -$14.14K | SELL | -1.94% | 78.70K | Jan 23 | ||
Jan 05, 2024 | CHIEF MEDICAL OFFICER | -2.51K | $9.43 | -$23.65K | SELL | -6.65% | 35.25K | Jan 03 - Jan 04 | ||
Oct 04, 2023 | CHIEF COMMERCIAL OFFICER | -3.09K | $8.25 | -$25.50K | SELL | -3.71% | 80.26K | Oct 03 | ||
Sep 05, 2023 | CHIEF FINANCIAL OFFICER | -457.00 | $14.71 | -$6.72K | SELL | -0.90% | 50.57K | Sep 05 | ||
Sep 05, 2023 | SENIOR VICE PRESIDENT, R&D | 1.49K | $14.71 | -$26.70K | GRANT | 2.49% | 61.17K | Aug 31 - Sep 05 | ||
Sep 05, 2023 | SVP, GC & CORPORATE SECRETARY | 1.49K | $14.71 | -$26.70K | GRANT | 2.62% | 58.10K | Aug 31 - Sep 05 | ||
Sep 05, 2023 | CHIEF EXECUTIVE OFFICER | 5.45K | $14.71 | -$65.53K | GRANT | 2.30% | 242.59K | Aug 31 - Sep 05 | ||
May 12, 2023 | CHIEF FINANCIAL OFFICER | -455.00 | $16.59 | -$7.55K | SELL | -0.88% | 51.03K | May 10 | ||
May 12, 2023 | SVP, GC & CORPORATE SECRETARY | -825.00 | $16.59 | -$13.69K | SELL | -1.44% | 56.61K | May 10 | ||
May 12, 2023 | SENIOR VICE PRESIDENT, R&D | -825.00 | $16.59 | -$13.69K | SELL | -1.37% | 59.21K | May 10 | ||
May 12, 2023 | SVP, CHIEF ACCOUNTING OFFICER | -558.00 | $16.49 | -$9.20K | SELL | -1.30% | 42.25K | May 10 - May 11 | ||
Apr 13, 2023 | CHIEF FINANCIAL OFFICER | -47.00 | $21.49 | -$1.01K | SELL | -0.09% | 51.49K | Apr 11 | ||
Feb 02, 2023 | SVP, GC & CORPORATE SECRETARY | 17.66K | $22.25 | -$57.63K | GRANT | 44.40% | 57.44K | Jan 31 - Feb 01 | ||
Feb 02, 2023 | SENIOR VICE PRESIDENT, R&D | 17.66K | $22.25 | -$57.63K | GRANT | 41.67% | 60.04K | Jan 31 - Feb 01 | ||
Feb 02, 2023 | CHIEF COMMERCIAL OFFICER | 18.47K | $21.75 | -$38.70K | GRANT | 29.04% | 82.07K | Jan 31 - Feb 01 | ||
Feb 02, 2023 | CHIEF FINANCIAL OFFICER | 18.66K | $21.75 | -$34.54K | GRANT | 56.77% | 51.53K | Jan 31 - Feb 01 | ||
Feb 02, 2023 | CHIEF EXECUTIVE OFFICER | 89.30K | $22.25 | -$182.36K | GRANT | 60.40% | 237.15K | Jan 31 - Feb 01 | ||
Feb 02, 2023 | SVP, CHIEF ACCOUNTING OFFICER | 7.97K | $21.87 | -$44.42K | GRANT | 22.88% | 42.80K | Jan 31 - Feb 02 | ||
Jan 26, 2023 | SVP, CHIEF ACCOUNTING OFFICER | -1.10K | $21.86 | -$23.98K | SELL | -3.05% | 34.84K | Jan 24 - Jan 25 | ||
Jan 26, 2023 | SENIOR VICE PRESIDENT, R&D | -2.06K | $21.50 | -$44.33K | SELL | -4.64% | 42.38K | Jan 24 | ||
Jan 26, 2023 | SVP, GC & CORPORATE SECRETARY | -2.06K | $21.50 | -$44.33K | SELL | -4.93% | 39.78K | Jan 24 | ||
Jan 26, 2023 | CHIEF EXECUTIVE OFFICER | -6.44K | $21.50 | -$138.50K | SELL | -4.18% | 147.85K | Jan 24 | ||
Jan 26, 2023 | CHIEF FINANCIAL OFFICER | -852.00 | $21.90 | -$18.66K | SELL | -2.53% | 32.87K | Jan 24 | ||
Jan 26, 2023 | CHIEF COMMERCIAL OFFICER | -1.55K | $21.90 | -$33.95K | SELL | -2.38% | 63.60K | Jan 24 | ||
Jan 06, 2023 | CHIEF EXECUTIVE OFFICER | -5.63K | $20.75 | -$116.72K | SELL | -3.52% | 154.29K | Jan 05 | ||
Jan 06, 2023 | CHIEF MEDICAL OFFICER | -2.49K | $20.75 | -$51.73K | SELL | -12.46% | 17.51K | Jan 04 - Jan 05 | ||
Oct 06, 2022 | CHIEF COMMERCIAL OFFICER | -3.04K | $25.68 | -$78.12K | SELL | -4.46% | 65.15K | Oct 04 | ||
Sep 15, 2022 | SVP, CHIEF ACCOUNTING OFFICER | -349.00 | $28.00 | -$9.77K | SELL | -0.96% | 35.93K | Sep 13 | ||
May 12, 2022 | SENIOR VICE PRESIDENT, R&D | -1.56K | $21.71 | -$33.94K | SELL | -3.46% | 43.67K | May 11 | ||
May 12, 2022 | SVP, GC & CORPORATE SECRETARY | -1.95K | $21.51 | -$41.94K | SELL | -4.45% | 41.84K | May 10 - May 12 | ||
May 12, 2022 | CHIEF FINANCIAL OFFICER | -2.20K | $21.51 | -$47.32K | SELL | -5.81% | 35.66K | May 10 - May 11 | ||
May 12, 2022 | SVP, CHIEF ACCOUNTING OFFICER | -881.00 | $21.72 | -$19.13K | SELL | -2.41% | 35.73K | May 10 - May 11 | ||
May 12, 2022 | DIRECTOR | -2.58K | $21.92 | -$56.46K | SELL | -1.72% | 146.92K | May 11 | ||
Feb 11, 2022 | CHIEF EXECUTIVE OFFICER | -4.83K | $27.84 | -$134.52K | SELL | -2.93% | 159.91K | Feb 10 | ||
Feb 02, 2022 | VP, CORP CONTROLLER AND CAO | 7.95K | $26.51 | -$21.15K | GRANT | 27.74% | 36.61K | Jan 31 | ||
Feb 02, 2022 | SVP, GC & CORPORATE SECRETARY | 8.49K | $27.40 | -$36.99K | GRANT | 24.05% | 43.79K | Jan 31 | ||
Feb 02, 2022 | SENIOR VICE PRESIDENT, R&D | 8.71K | $27.40 | -$30.82K | GRANT | 23.86% | 45.23K | Jan 31 | ||
Feb 02, 2022 | CHIEF COMMERCIAL OFFICER | 8.71K | $27.40 | -$30.82K | GRANT | 14.88% | 67.30K | Jan 31 | ||
Feb 02, 2022 | CHIEF FINANCIAL OFFICER | 8.60K | $27.40 | -$33.92K | GRANT | 29.41% | 37.85K | Jan 31 | ||
Feb 02, 2022 | CHIEF EXECUTIVE OFFICER | 33.03K | $27.40 | -$131.88K | GRANT | 25.08% | 164.75K | Jan 31 | ||
Jan 26, 2022 | VP, CORP CONTROLLER AND CAO | -934.00 | $24.58 | -$22.95K | SELL | -3.16% | 28.66K | Jan 24 | ||
Jan 26, 2022 | SENIOR VICE PRESIDENT, R&D | -1.88K | $24.98 | -$46.84K | SELL | -4.88% | 36.52K | Jan 24 | ||
Jan 26, 2022 | CHIEF COMMERCIAL OFFICER | -1.88K | $24.98 | -$46.84K | SELL | -3.10% | 58.58K | Jan 24 | ||
Jan 26, 2022 | SVP, GC & CORPORATE SECRETARY | -2.25K | $24.98 | -$56.20K | SELL | -5.99% | 35.30K | Jan 24 | ||
Jan 26, 2022 | CHIEF FINANCIAL OFFICER | -2.06K | $24.98 | -$51.53K | SELL | -6.59% | 29.25K | Jan 24 | ||
Jan 26, 2022 | CHIEF EXECUTIVE OFFICER | -7.87K | $24.98 | -$196.67K | SELL | -5.64% | 131.71K | Jan 24 | ||
Jan 12, 2022 | SVP, GC & CORPORATE SECRETARY | 0.00 | $27.40 | -$137.00K | GRANT | 0.00% | 37.55K | Jan 10 - Jan 11 | ||
Jan 12, 2022 | SENIOR VICE PRESIDENT, R&D | 2.50K | $27.40 | -$68.50K | GRANT | 6.96% | 38.40K | Jan 10 - Jan 11 | ||
Jan 12, 2022 | CHIEF FINANCIAL OFFICER | 0.00 | $27.40 | -$205.50K | GRANT | 0.00% | 31.32K | Jan 10 - Jan 11 | ||
Jan 06, 2022 | CHIEF EXECUTIVE OFFICER | -17.33K | $30.08 | -$521.41K | SELL | -11.05% | 139.58K | Jan 04 - Jan 05 | ||
Nov 18, 2021 | DIRECTOR | -31.80K | $29.39 | -$934.60K | SELL | -17.54% | 149.49K | Nov 16 | ||
Nov 09, 2021 | DIRECTOR | 0.00 | $21.23 | -$100.00K | SELL-OPTIONS | 0.00% | 181.29K | Nov 05 | ||
Nov 03, 2021 | DIRECTOR | -8.50K | $29.69 | -$252.40K | SELL | -30.36% | 19.50K | Feb 04 - Nov 02 | ||
Oct 08, 2021 | DIRECTOR | 0.00 | $21.24 | -$600.96K | SELL-OPTIONS | 0.00% | 189.79K | Oct 07 | ||
Oct 05, 2021 | CHIEF COMMERCIAL OFFICER | -3.06K | $24.77 | -$75.75K | SELL | -4.81% | 60.46K | Oct 04 | ||
Aug 17, 2021 | CHIEF COMMERCIAL OFFICER | 3.09K | $17.12 | -$24.09K | GRANT | 5.12% | 63.52K | Aug 13 - Aug 17 | ||
Aug 17, 2021 | CHIEF EXECUTIVE OFFICER | 9.66K | $17.12 | -$134.14K | GRANT | 6.56% | 156.91K | Aug 13 - Aug 17 | ||
Aug 17, 2021 | CHIEF MEDICAL OFFICER | 3.09K | $17.12 | -$24.09K | GRANT | 6.95% | 47.61K | Aug 13 - Aug 17 | ||
Aug 17, 2021 | SENIOR VICE PRESIDENT, R&D | 3.09K | $17.12 | -$24.09K | GRANT | 9.48% | 35.73K | Aug 13 - Aug 17 | ||
Aug 17, 2021 | SVP, GC & CORPORATE SECRETARY | 3.09K | $17.12 | -$24.09K | GRANT | 8.98% | 37.55K | Aug 13 - Aug 17 | ||
Aug 17, 2021 | CHIEF FINANCIAL OFFICER | 3.09K | $17.12 | -$24.09K | GRANT | 10.96% | 31.32K | Aug 13 - Aug 17 | ||
Jul 29, 2021 | CHIEF MEDICAL OFFICER | -1.25K | $13.81 | -$17.26K | SELL | -2.73% | 44.52K | Jul 28 | ||
Jun 03, 2021 | CHIEF EXECUTIVE OFFICER | -9.56K | $14.62 | -$139.80K | SELL | -6.10% | 147.25K | Jun 01 - Jun 02 | ||
May 13, 2021 | SENIOR VICE PRESIDENT, R&D | -3.13K | $19.30 | -$60.31K | SELL | -8.97% | 31.71K | May 11 - May 12 | ||
May 13, 2021 | CHIEF MEDICAL OFFICER | -750.00 | $19.30 | -$14.47K | SELL | -1.62% | 45.59K | May 11 - May 12 | ||
May 13, 2021 | SVP, GC & CORPORATE SECRETARY | -3.25K | $19.30 | -$62.73K | SELL | -8.62% | 34.45K | May 11 - May 12 | ||
May 13, 2021 | CHIEF FINANCIAL OFFICER | -4.00K | $19.30 | -$77.20K | SELL | -12.41% | 28.22K | May 11 - May 12 | ||
May 13, 2021 | DIRECTOR | -2.15K | $19.58 | -$42.02K | SELL | -1.14% | 186.79K | May 11 | ||
Apr 20, 2021 | DIRECTOR | 0.00 | $21.23 | -$100.00K | SELL-OPTIONS | 0.00% | 188.94K | Apr 16 | ||
Mar 19, 2021 | DIRECTOR | -7.73K | $21.84 | -$324.16K | SELL | -3.93% | 188.94K | Mar 17 | ||
Feb 18, 2021 | SENIOR VICE PRESIDENT, R&D | -2.50K | $28.01 | -$70.03K | SELL | -6.70% | 34.83K | Feb 17 - Feb 18 | ||
Feb 09, 2021 | CHIEF MEDICAL OFFICER | -2.25K | $31.50 | -$70.86K | SELL | -4.63% | 46.34K | Feb 05 - Feb 08 | ||
Feb 09, 2021 | CHIEF COMMERCIAL OFFICER | -2.25K | $31.50 | -$70.86K | SELL | -3.65% | 59.34K | Feb 05 - Feb 08 | ||
Feb 09, 2021 | SENIOR VICE PRESIDENT, R&D | -4.50K | $31.50 | -$141.73K | SELL | -10.76% | 37.33K | Feb 05 - Feb 08 | ||
Feb 09, 2021 | SVP, GC & CORPORATE SECRETARY | -4.50K | $31.50 | -$141.73K | SELL | -10.66% | 37.70K | Feb 05 - Feb 08 | ||
Feb 09, 2021 | CHIEF FINANCIAL OFFICER | -4.50K | $31.50 | -$141.73K | SELL | -12.25% | 32.22K | Feb 05 - Feb 08 | ||
Feb 09, 2021 | CHIEF EXECUTIVE OFFICER | -9.63K | $31.50 | -$303.17K | SELL | -5.78% | 156.81K | Feb 05 - Feb 08 | ||
Feb 03, 2021 | CHIEF COMMERCIAL OFFICER | -1.13K | $29.83 | -$33.59K | SELL | -1.93% | 57.09K | Feb 02 - Feb 03 | ||
Feb 03, 2021 | CHIEF MEDICAL OFFICER | -1.81K | $28.91 | -$52.41K | SELL | -3.95% | 44.09K | Feb 03 | ||
Feb 03, 2021 | SENIOR VICE PRESIDENT, R&D | -3.63K | $28.91 | -$104.80K | SELL | -8.85% | 37.33K | Feb 03 | ||
Feb 03, 2021 | SVP, GC & CORPORATE SECRETARY | -3.17K | $28.91 | -$91.79K | SELL | -7.77% | 37.70K | Feb 03 | ||
Feb 03, 2021 | CHIEF FINANCIAL OFFICER | -3.63K | $28.91 | -$104.80K | SELL | -10.11% | 32.22K | Feb 03 | ||
Feb 03, 2021 | CHIEF EXECUTIVE OFFICER | -2.41K | $28.91 | -$69.56K | SELL | -1.59% | 148.94K | Feb 03 | ||
Feb 02, 2021 | CHIEF MEDICAL OFFICER | 3.19K | $30.75 | -$55.75K | GRANT | 7.46% | 45.91K | Jan 31 - Feb 02 | ||
Feb 02, 2021 | SENIOR VICE PRESIDENT, R&D | 1.38K | $30.75 | -$111.47K | GRANT | 3.27% | 43.46K | Jan 31 - Feb 02 | ||
Feb 02, 2021 | SVP, GC & CORPORATE SECRETARY | 1.82K | $30.75 | -$97.63K | GRANT | 4.67% | 40.88K | Jan 31 - Feb 02 | ||
Feb 02, 2021 | CHIEF EXECUTIVE OFFICER | 6.27K | $29.91 | -$261.27K | GRANT | 4.32% | 151.34K | Jan 31 - Feb 02 | ||
Feb 02, 2021 | CHIEF FINANCIAL OFFICER | 1.38K | $30.75 | -$111.47K | GRANT | 3.99% | 35.85K | Jan 31 - Feb 02 | ||
Feb 02, 2021 | DIRECTOR | 0.00 | $20.42 | -$516.50K | SELL-OPTIONS | 0.00% | 196.67K | Feb 02 | ||
Jan 07, 2021 | SVP, GC & CORPORATE SECRETARY | -1.38K | $26.83 | -$36.92K | SELL | -5.41% | 24.05K | Jan 05 - Jan 06 | ||
Jan 07, 2021 | CHIEF EXECUTIVE OFFICER | -6.88K | $26.83 | -$184.48K | SELL | -7.26% | 87.82K | Jan 05 - Jan 06 | ||
Dec 16, 2020 | — | -5.55K | $26.02 | -$144.38K | SELL | -2.74% | 196.67K | Dec 15 | ||
Dec 04, 2020 | — | -10.89K | $23.43 | -$184.85K | GIFT | -5.11% | 202.22K | Nov 19 - Dec 02 |
PREGUNTAS FRECUENTES
¿Es legal el uso de información privilegiada?
Las operaciones con información privilegiada son legales siempre que se notifiquen a la Comisión de Bolsa y Valores (SEC). El comercio ilegal de valores se produce cuando la persona con información privilegiada viola un deber fiduciario o no informa de sus operaciones.
¿Cuáles son algunos ejemplos de manipulación del mercado?
Las operaciones con información privilegiada, los esquemas de pump and dump, el front running y las operaciones de lavado son ejemplos de manipulación del mercado. Los inversores que siguen el movimiento de activos con información privilegiada deben pensar atentamente por qué estos operadores con información privilegiada están negociando sus acciones antes de seguir adelante.
Explora operaciones con información privilegiada sobre todos los valores.
Noticias de operaciones con información privilegiada sobre TVTX
No se han encontrado noticias